Prospector Partners LLC Purchases 355 Shares of AstraZeneca PLC (NASDAQ:AZN)

Prospector Partners LLC boosted its position in AstraZeneca PLC (NASDAQ:AZN) by 5.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 7,055 shares of the company’s stock after purchasing an additional 355 shares during the period. Prospector Partners LLC’s holdings in AstraZeneca were worth $550,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of AZN. McClarren Financial Advisors Inc. boosted its stake in shares of AstraZeneca by 320.8% during the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock valued at $25,000 after purchasing an additional 247 shares during the period. GHP Investment Advisors Inc. bought a new stake in AstraZeneca during the 2nd quarter valued at about $26,000. Capital Performance Advisors LLP purchased a new stake in AstraZeneca in the 3rd quarter valued at about $28,000. Pathway Financial Advisers LLC purchased a new stake in AstraZeneca in the 1st quarter valued at about $29,000. Finally, CANADA LIFE ASSURANCE Co increased its position in shares of AstraZeneca by 40.6% during the first quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock worth $34,000 after acquiring an additional 146 shares during the period. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Analyst Upgrades and Downgrades

AZN has been the topic of a number of recent research reports. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. TD Cowen increased their target price on shares of AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a report on Monday, August 12th. UBS Group upgraded shares of AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Finally, Erste Group Bank raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $89.75.

AstraZeneca Stock Up 1.2 %

AZN stock opened at $66.40 on Tuesday. The stock has a market capitalization of $205.88 billion, a PE ratio of 31.77, a price-to-earnings-growth ratio of 1.20 and a beta of 0.47. AstraZeneca PLC has a 52 week low of $60.47 and a 52 week high of $87.68. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. The firm has a 50 day moving average of $73.19 and a 200 day moving average of $77.72.

AstraZeneca (NASDAQ:AZN) last issued its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. The company had revenue of $13.57 billion during the quarter, compared to analyst estimates of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The firm’s quarterly revenue was up 18.0% on a year-over-year basis. During the same quarter last year, the business posted $0.87 EPS. Sell-side analysts forecast that AstraZeneca PLC will post 4.1 earnings per share for the current year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.